InsiderTrades

Form 4 for IOVA IOVANCE BIOTHERAPEUTICS, INC.

Accepted 2023-01-05 00:00:00 ET · period of report 2023-01-03 · accession 0001104659-23-001600 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-01-05 2023-01-03 IOVA Bellemin Jean-Marc CFO M - OptEx $0.00 +18.9K 28.4K +198% $0
D 2023-01-05 2023-01-03 IOVA Bellemin Jean-Marc CFO F - Tax $6.11 -10.6K 17.8K -37% -$64.5K
D 2023-01-05 2023-01-03 IOVA Bellemin Jean-Marc CFO M - OptEx $0.00 -18.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-01-03 M A 18,850 $0.00 28,354 D — — (F1) This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021. (F2) Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
2 Common Common Stock 2023-01-03 F D 10,553 $6.11 17,801 D — — (F3) Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. (F4) Represents common stock remaining after deducting the common stock withheld for taxes.
3 Derivative Restricted Stock Units 2023-01-03 M D 18,850 $0.00 0 D — · — to — 18,850 Common stock (F5) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F6) As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023.